STM JOURNALS

Research & Reviews: A Journal of
Medicine

https://journals.stmjournals.com/rrjom/

ISSN: 2249-8648 (Online)
ISSN: 2348-7917 (Print)
Volume 14, Issue 2, 2024
May–August
DOI (Journal): 10.37591/RRJoM

Review RRJoM

Metabolic Reprogramming in Carcinogenesis: An Overview

Sharique Ahmad[1,*], Nishat I. Iram[2], Priyesh Srivastava[3], Sidrah Fatima[4], Pushpendra D. Pratap[5], Raushan Kumar[6]

Abstract

Metabolic reprogramming is a crucial mechanism via which cells modify their metabolic pathways to adjust to changes in the environment and maintain growth, survival, and function. This phenomenon is of utmost importance in a wide range of physiological and pathological situations, specifically in cancer, immunological responses, and stem cell biology. In cancer, metabolic reprogramming facilitates fast cell growth and survival, as demonstrated by the Warburg effect, where cancer cells prioritize glycolysis over oxidative phosphorylation, even when oxygen is available. This alteration allows for the generation of ATP and metabolic intermediates that are crucial for biosynthesis and growth. Crucial controllers, including oncogenes and tumor suppressors, coordinate these alterations in metabolism by regulating glycolytic enzymes and glucose transporters. Cancer cells demonstrate metabolic flexibility by utilizing oxidative phosphorylation in addition to glycolysis, adjusting their metabolism based on environmental factors and energy requirements. Signaling molecules like AMPK and mTOR have essential functions in maintaining the equilibrium of these pathways. This review paper offers a thorough examination of the mechanisms that drive metabolic reprogramming, its significance in disease, and its possible therapeutic uses. Ongoing research holds the potential for innovative therapeutic approaches in several diseases, such as cancer, immunological disorders, and degenerative ailments. As our comprehension of cellular metabolism becomes more profound, our capacity to control it for therapeutic advantage will also increase.

Keywords: Metabolic reprogramming, Mitochondrial membrane potential, Carcinogenesis, Warburg effect, glycolysis, oncogenes

***Author for Correspondence**
Sharique Ahmad
E-mail: diagnopath@gmail.com

[1]Professor, Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh, India
[2-4]Juinor Resident, Department Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh, India
[5]Research Scholar, Department of Biochemistry, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh, India
[6]Research Analyst, Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh, India

Received Date: June 07, 2024
Accepted Date: June 26, 2024
Published Date: August 22, 2024

Citation: Sharique Ahmad, Nishat I. Iram, Priyesh Srivastava, Sidrah Fatima, Pushpendra D. Pratap, Raushan Kumar. Metabolic Reprogramming in Carcinogenesis: An Overview. Research & Reviews: A Journal of Medicine. 2024; 14(2): 32–38p.

INTRODUCTION

Metabolic reprogramming involves the crucial issue of amino acid metabolism, specifically glutaminolysis. Glutamine is an essential component for the tricarboxylic acid (TCA) cycle and the production of nucleotides, which enables the rapid growth of cancer cells. Likewise, changes in lipid metabolism, such as increased production and absorption of fatty acids, supply essential components for the creation of cell membranes and signaling molecules [1]. Lipid droplets serve as energy reserves that are recruited in response to metabolic stress. The consequences of metabolic reprogramming go beyond just cancer. Metabolic changes are the foundation for the activation, differentiation, and effector actions of immune cells. T cells that are activated undergo a metabolic shift from oxidative metabolism to glycolysis to facilitate their growth and generation of cytokines

[2, 3]. Manipulating the metabolic activity of immune cells has the potential to boost immune responses against infections and cancer, and to cure autoimmune illnesses. Pluripotency and differentiation potential in stem cell biology are associated with distinct metabolic profiles. Embryonic stem cells predominantly depend on glycolysis for their energy production, but the process of differentiation entails a transition toward oxidative phosphorylation. Modulating these metabolic pathways can impact the determination of stem cell fate, offering prospects for regenerative medicine. Although there has been notable advancement, there are still obstacles in comprehensively grasping and directing metabolic reprogramming. Additional clarification is needed to understand complex regulatory networks and their precise functions in different contexts. Metabolomics and single-cell technologies are anticipated to yield a more profound understanding of metabolic diversity and changes across time [4, 5]. Converting these observations into successful treatments requires addressing challenges associated with precision, harmful effects, and resilience. Metabolic reprogramming is a complex and versatile mechanism that is crucial in numerous biological situations

Metabolic reprogramming, the process by which cells alter their metabolic pathways to adapt to environmental changes and sustain growth and survival, has emerged as a critical area of study in cell biology and medicine [6, 7]. This phenomenon is especially pertinent in the context of cancer, immune responses, and stem cell biology, where metabolic changes underpin key cellular functions and fate decisions [8]. This review seeks to offer a thorough examination of metabolic reprogramming, emphasizing recent advancements, underlying mechanisms, and possible therapeutic uses. Metabolic reprogramming involves modifying the metabolic pathways within cells to facilitate different biological processes, such as growth, proliferation, and survival.

Mechanisms of Metabolic Reprogramming

Metabolic reprogramming involves extensive alterations in cellular metabolism, including changes in glycolysis, oxidative phosphorylation, and the utilization of alternative nutrient sources [9, 10].

Regular Metabolism: In regular cells, metabolism is closely controlled to fulfill cellular energy requirements, uphold redox equilibrium, and facilitate biosynthesis. Glucose is mainly broken down through glycolysis in the cytoplasm to produce pyruvate. The pyruvate then enters the mitochondria for additional oxidation in the tricarboxylic acid (TCA) cycle, resulting in the production of ATP through oxidative phosphorylation (OXPHOS) (4).

- *Glycolysis and the Warburg Effect:* The Warburg effect is a prominent instance of metabolic reprogramming, in which cancer cells exhibit a preference for utilizing glycolysis as their main energy production pathway, even when there is enough oxygen available (aerobic glycolysis) [11]. This shift allows cancer cells to rapidly generate ATP and produce metabolic intermediates necessary for cell growth and division. Key regulators of this process include oncogenes (e.g., MYC, KRAS) and tumor suppressors (e.g., TP53) that modulate the expression of glycolytic enzymes and glucose transporters [11, 12]. Cancer cells demonstrate elevated levels of glycolytic enzymes, including hexokinase, phosphofructokinase, and pyruvate kinase, which enhance the conversion of glucose into pyruvate [13]. A key step in the acidity of the tumor's internal environment is the conversion of pyruvate to lactate, which is subsequently released from the cell.
- Oxidative phosphorylation (OXPHOS) is a key process in mitochondrial metabolism that, under typical circumstances, produces a lot of ATPS, unlike glycolysis [14]. Cancer cells and other proliferative cells often show flexible metabolic states, capable of switching between glycolysis and OXPHOS depending on their needs and environmental conditions. The balance between these pathways is tightly regulated by signaling molecules such as AMPK and mTOR, which respond to cellular energy status and nutrient availability [3]. While the Warburg effect highlights increased glycolysis, mitochondrial metabolism is also dysregulated in cancer. Mutations in genes encoding mitochondrial enzymes (e.g., isocitrate dehydrogenase) or electron transport

chain complexes can disrupt mitochondrial function and contribute to metabolic reprogramming [10, 15].

Amino Acid Metabolism: Amino acids, particularly glutamine, play crucial roles in metabolic reprogramming. Glutamine is a key substrate for the tricarboxylic acid (TCA) cycle and nucleotide biosynthesis. Cancer cells often exhibit increased glutamine uptake and metabolism, a process known as glutaminolysis, which supports rapid cell growth and proliferation [16, 17].

Lipid Metabolism: Alterations in lipid metabolism are also integral to metabolic reprogramming. Enhanced fatty acid synthesis and uptake provide building blocks for membrane synthesis and signaling molecules. Additionally, lipid droplets serve as energy reservoirs that can be mobilized during periods of metabolic stress [18].

Implications in Disease and Therapy

- *Cancer:* One characteristic of cancer is metabolic reprogramming, which promotes tumor growth and survival. A new and exciting therapeutic approach involves focusing on metabolic pathways. Inhibitors of glycolysis (such 2-deoxy-D-glucose) and glutaminase, for instance, are presently the subject of investigation in clinical trials. Additionally, understanding the metabolic process diversity inside tumors can aid in the development of personalized treatments [1]. In order to sustain their fast growth and survival, cancer cells display significant metabolic changes. Because cancer cells preferentially use glycolysis even when oxygen is present, the Warburg effect is defined by an increase in lactate production (aerobic glycolysis). By rerouting carbon from glucose into biosynthetic pathways, cancer cells are able to fuel their own growth [19]. Otto Warburg's name is given to the tendency of cancer cells to use glycolysis for ATP synthesis more favorably, even when oxygen is present. This phenomenon is called the Warburg effect. According to Lu, Tan, and Cai [19], cancer cells activate a metabolic switch that enables them to produce energy quickly and redirect glycolytic intermediates into pathways that help them grow.

Key Players in Cancer Metabolic Reprogramming

- *Oncogenes and Tumor Suppressors:* Mutations in oncogenes (e.g., MYC, PI3K) and tumor suppressors (e.g., p53) can drive metabolic reprogramming by altering the expression of metabolic enzymes and transporters [6].
- *Hypoxia-Inducible Factor 1 (HIF-1):* Hypoxic conditions within the tumor microenvironment stabilize HIF-1, which upregulates the expression of glycolytic enzymes and glucose transporters, promoting glycolysis. Hypoxic conditions in the tumor microenvironment stabilize HIF-1, which transcriptionally activates genes involved in glycolysis (e.g., GLUT1, LDHA) and angiogenesis. HIF-1 activation promotes adaptation to low oxygen levels but also contributes to the Warburg effect [20].
- *Metabolic Enzymes:* Enzymes involved in glycolysis (e.g., hexokinase, pyruvate kinase), the TCA cycle (e.g., isocitrate dehydrogenase), and fatty acid metabolism (e.g., fatty acid synthase) are often dysregulated in cancer cells, contributing to metabolic reprogramming [21].
- *Nutrient Sensing Pathways:* Signaling pathways such as mTOR (mechanistic target of rapamycin) and AMP-activated protein kinase (AMPK) integrate nutrient availability and energy status to regulate metabolism. Dysregulation of these pathways can drive metabolic reprogramming in cancer. AMP-activated protein kinase (AMPK) acts as a cellular energy sensor and can inhibit anabolic pathways while stimulating catabolic processes under low-energy conditions [22].

Therapeutic Implications: A new and potentially effective method of treating cancer is by focusing on the cells' metabolic weaknesses. Some examples of compounds being studied as possible anticancer treatments are 2-deoxyglucose, inhibitors of glycolysis, electron transport chain inhibitors, and fatty acid synthase inhibitors [23, 24].

Therapeutic Targeting of Metabolic Reprogramming

Glycolysis Inhibitors

- Compounds targeting glycolytic enzymes or glucose transporters aim to disrupt the energy production and biosynthetic capacity of cancer cells [25].
- Examples include 2-deoxyglucose (2-DG) and inhibitors of lactate dehydrogenase (LDH).

Mitochondrial Metabolism

- Inhibitors targeting mitochondrial function, such as electron transport chain inhibitors (e.g., metformin) or mitochondrial uncouplers, can induce metabolic stress and apoptosis in cancer cells [26].

Fatty Acid Synthesis

- Cancer cells often overexpress fatty acid synthase (FASN), an enzyme involved in fatty acid production. FASN inhibitors, which target fatty acid synthesis enzymes, are promising cancer-preventive therapies [27].

Immunometabolism in Cancer: Metabolic reprogramming is also necessary for immune cells to fulfill activation, differentiation, and effector tasks. In order to facilitate fast proliferation and cytokine generation, activated T cells, for instance, switch from oxidative metabolism to glycolysis. Improving immunological responses to cancer, infections, and autoimmune disorders may be possible through regulating immune cell metabolism [28].

Metabolic Landscape in Cancer Cells

- *Aerobic Glycolysis (Warburg Effect):* Even when oxygen is present, cancer cells may enhance glucose absorption and aerobic glycolysis, resulting in lactate generation. Quick ATP production and biosynthetic metabolic intermediates are both supported by this metabolic phenotype [19].
- *Altered Lipid and Amino Acid Metabolism:* Cancer cells rewire lipid metabolism to support membrane synthesis and signaling molecules. Additionally, amino acid metabolism, particularly glutamine and serine metabolism, is altered to provide substrates for nucleotide synthesis and redox balance [9, 16].

Immune Cell Metabolism in the Tumour Microenvironment

- *Tumor-Infiltrating Lymphocytes (TILs):* T cells within the tumor microenvironment often exhibit metabolic exhaustion characterized by impaired mitochondrial function, decreased glycolysis, and altered lipid metabolism. These metabolic alterations compromise T cell effector functions, contributing to immune evasion by cancer cells [29].
- *Myeloid-Derived Suppressor Cells (MDSCs) and Tumor-Associated Macrophages (TAMs):* MDSCs and TAMs undergo metabolic reprogramming to support their immunosuppressive functions within the tumor microenvironment. This includes increased glycolysis, fatty acid oxidation, and altered amino acid metabolism [24].

Immunometabolism Interactions and Therapeutic Implications

- *Metabolic Competition:* Cancer cells compete with immune cells for nutrients within the tumor microenvironment, limiting the availability of metabolites essential for immune cell function [30].
- *Immunotherapy Resistance:* One reason why some cancer cells and immune cells become resistant to immunotherapy is because of metabolic changes. Strategies targeting cancer metabolism or modulating immune cell metabolism have shown promise in overcoming resistance and enhancing the efficacy of immunotherapy [31].
- *Metabolic Targeting for Immunotherapy:* Combining immunotherapy with metabolic interventions, such as inhibitors of glycolysis or fatty acid metabolism, holds potential such that treatment results can be improved, and anti-tumor immune responses can be enhanced [32].

Stem Cell Biology: Stem cells exhibit unique metabolic profiles that are linked to their pluripotency and differentiation potential. Embryonic stem cells rely heavily on glycolysis, while differentiation often involves a metabolic shift towards oxidative phosphorylation. There is potential for regenerative medicine in the manipulation of metabolic pathways to affect stem cell fate decisions [33].

Stem cell biology intersects with metabolic reprogramming in various contexts, particularly concerning the metabolic flexibility and adaptations of stem cells to support self-renewal, differentiation, and tissue regeneration. Here's an exploration of stem cell biology in metabolic reprogramming:

Metabolic Characteristics of Stem Cells

- *Pluripotent Stem Cells:* Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) exhibit high metabolic plasticity, utilizing both glycolysis and oxidative phosphorylation (OXPHOS) to meet energy demands. They favor glycolysis for rapid proliferation but can switch to OXPHOS upon differentiation [2].
- *Tissue-Specific Stem Cells:* Different adult stem cell types, such as brain stem cells (NSCs) and hematopoietic stem cells (HSCs), have metabolic profiles that are adapted to their specific environment and the functions they perform [34].

Metabolic Regulation of Stem Cell Fate

- *Glycolytic Regulation of Pluripotency:* ESCs and iPSCs maintain pluripotency partly through active glycolysis, which supports the production of metabolic intermediates for biosynthesis and redox balance. Inhibition of glycolysis can promote differentiation (5).
- *Oxidative Metabolism in Differentiation:* As stem cells commit to differentiation, there is a metabolic shift towards oxidative metabolism, accompanied by increased mitochondrial biogenesis and respiratory capacity. This metabolic transition is critical for cellular differentiation and tissue development [33].

Metabolic Reprogramming in Stem Cell Niches

- *Metabolic Crosstalk in Stem Cell Niches:* The metabolic microenvironment of stem cell niches, characterized by gradients of oxygen, nutrients, and signaling molecules, influences stem cell behavior and fate decisions. Stem cell self-renewal and differentiation are controlled by metabolic signals from nearby cells and components of the extracellular matrix.
- *Metabolism and Stem Cell Quiescence:* Quiescent stem cells in adult tissues exhibit a distinct metabolic profile characterized by reduced glycolysis and reliance on fatty acid oxidation (FAO). Metabolic alterations can influence the balance between stem cell quiescence and activation [35].

Implications for Regenerative Medicine and Disease

- *Metabolic Reprogramming in Regeneration:* Understanding the metabolic requirements of stem cells is crucial for enhancing regenerative capacity in tissue engineering and regenerative medicine approaches.
- *Metabolic Dysregulation in Disease:* Dysregulated metabolism can impair stem cell function and contribute to disease pathogenesis, such as in cancer stem cells and degenerative diseases. Targeting metabolic pathways in stem cells may offer therapeutic avenues for disease intervention [24].

Future Directions and Challenges

- Despite significant progress, many challenges remain in the field of metabolic reprogramming. A deeper understanding of the complex regulatory networks and their context-specific roles is essential. Advances in metabolomics and single-cell technologies are expected to provide new insights into metabolic heterogeneity and dynamics. Furthermore, translating metabolic insights into effective therapies requires overcoming issues related to specificity, toxicity, and resistance.

Optimizing the metabolic milieu during stem cell culture and transplantation is critical for improving the efficacy and safety of stem cell-based therapies.

- Advancements in single-cell metabolomics technologies will facilitate the comprehensive characterization of metabolic heterogeneity within stem cell populations and their niches.
- We can learn more about the processes that control stem cell fate and function if we can understand how metabolic pathways interact with other signaling networks, like cell signaling pathways and epigenetic regulation.

CONCLUSION

Several physiological and pathological settings rely heavily on metabolic reprogramming, an intricate and ever-changing process. Continued research in this area holds promise for novel therapeutic strategies across a range of diseases, including cancer, immune disorders, and degenerative conditions. As our understanding of cellular metabolism deepens, so will our ability to manipulate it for therapeutic benefit.

REFERENCES

1. Phan LM, Yeung SCJ, Lee MH. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 2014 Mar;11(1):1–19.
2. Nishimura K, Fukuda A, Hisatake K. Mechanisms of the Metabolic Shift during Somatic Cell Reprogramming. Int J Mol Sci. 2019 May 7;20(9):2254.
3. Schiliro C, Firestein BL. Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. Cells. 2021 Apr 29;10(5):1056.
4. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016 May;2(5):e1600200.
5. Tsogtbaatar E, Landin C, Minter-Dykhouse K, Folmes CDL. Energy Metabolism Regulates Stem Cell Pluripotency. Front Cell Dev Biol. 2020; 8:87.
6. Navarro C, Ortega Á, Santeliz R, Garrido B, Chacín M, Galban N, et al. Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches. Pharmaceutics. 2022 Jun 19;14(6):1303.
7. Strickland M, Stoll EA. Metabolic Reprogramming in Glioma. Front Cell Dev Biol. 2017; 5:43.
8. Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021 Feb 5;20(1):28.
9. Jin J, Byun JK, Choi YK, Park KG. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023 Apr;55(4):706–15.
10. Khanijou JK, Kulyk H, Bergès C, Khoo LW, Ng P, Yeo HC, et al. Metabolomics and modelling approaches for systems metabolic engineering. Metab Eng Commun. 2022 Dec;15:e00209.
11. Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019 Jul 3;95(7):912–9.
12. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016 Mar;41(3):211–8.
13. Justus CR, Sanderlin EJ, Yang LV. Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. Int J Mol Sci. 2015 May 15;16(5):11055–86.
14. Paul S, Ghosh S, Kumar S. Tumor glycolysis, an essential sweet tooth of tumor cells. Semin Cancer Biol. 2022 Nov; 86:1216–30.
15. Orang AV, Petersen J, McKinnon RA, Michael MZ. Micromanaging aerobic respiration and glycolysis in cancer cells. Mol Metab. 2019 May; 23:98–126.
16. Jin J, Byun JK, Choi YK, Park KG. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023 Apr;55(4):706–15.
17. Lukey MJ, Wilson KF, Cerione RA. Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med Chem. 2013 Sep;5(14):1685–700.
18. Zeković M, Bumbaširević U, Živković M, Pejčić T. Alteration of Lipid Metabolism in Prostate Cancer: Multifaceted Oncologic Implications. Int J Mol Sci. 2023 Jan 11;24(2):1391.

19. Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015 Jan 28;356(2 Pt A):156–64.
20. Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target. Int J Mol Sci. 2021 May 27;22(11):5703.
21. Sreedhar A, Zhao Y. Dysregulated metabolic enzymes and metabolic reprogramming in cancer cells. Biomed Rep. 2018 Jan;8(1):3–10.
22. Robles-Flores M, Moreno-Londoño AP, Castañeda-Patlán MC. Signaling Pathways Involved in Nutrient Sensing Control in Cancer Stem Cells: An Overview. Front Endocrinol. 2021;12:627745.
23. Li X, Jiang O, Wang S. Molecular mechanisms of cellular metabolic homeostasis in stem cells. Int J Oral Sci. 2023 Dec 1;15(1):52.
24. Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021 Oct 7;6(1):362.
25. Zhang Y, Li Q, Huang Z, Li B, Nice EC, Huang C, et al. Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies. Cancers. 2022 Sep 21;14(19):4568.
26. Yang Y, An Y, Ren M, Wang H, Bai J, Du W, et al. The mechanisms of action of mitochondrial targeting agents in cancer: inhibiting oxidative phosphorylation and inducing apoptosis. Front Pharmacol. 2023; 14:1243613.
27. Vanauberg D, Schulz C, Lefebvre T. Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies. Oncogenesis. 2023 Mar 18;12(1):16.
28. Singer K, Cheng WC, Kreutz M, Ho PC, Siska PJ. Immunometabolism in cancer at a glance. Dis Model Mech. 2018 Aug 2;11(8): dmm034272.
29. Lim AR, Rathmell WK, Rathmell JC. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. eLife. 2020 May 5;9: e55185.
30. Zhang X, Song W, Gao Y, Zhang Y, Zhao Y, Hao S, et al. The Role of Tumor Metabolic Reprogramming in Tumor Immunity. Int J Mol Sci. 2023 Dec 13;24(24):17422.
31. Bader JE, Voss K, Rathmell JC. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020 Jun 18;78(6):1019–33.
32. Leone RD, Powell JD. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy. Cancer Immunol Res. 2021 Mar;9(3):255–60.
33. Rigaud VOC, Hoy R, Mohsin S, Khan M. Stem Cell Metabolism: Powering Cell-Based Therapeutics. Cells. 2020 Nov 16;9(11):2490.
34. Redondo PA, Pavlou M, Loizidou M, Cheema U. Elements of the niche for adult stem cell expansion. J Tissue Eng. 2017; 8:2041731417725464.
35. Gattazzo F, Urciuolo A, Bonaldo P. Extracellular matrix: a dynamic microenvironment for stem cell niche. Biochim Biophys Acta. 2014 Aug;1840(8):2506–19.

